Skip To Main Content
Brydon Panozzo on Muck Rack

Brydon Panozzo

As seen in: Wiley Online Library
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Brydon

Contact Brydon, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Dynamic risk stratification using early CAR-T expansion in R/R LBCL treated with axicabtagene ciloleucel

|
By Malignant Haematology, Samuel Robinson, Brydon Panozzo
| Wiley Online Library Verified
INTRODUCTION Chimeric antigen receptor (CAR) T-cell therapy has demonstrated significant clinical benefit to patients with relapsed and refractory large B-cell lymphoma (LBCL).1-3 Prior analyses of CAR-T expansion in vivo have reported variable associated efficacy and toxicity.4-10 However, existing studies show significant variability in cohorts, disease subtypes, CAR-T products and analytical methods. In the largest real-world study to date, Hamilton et al.
Open in Who Shared Issue with article?
See all 1 articles